CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: In vitro drug sensitivity and outcome

The outcome for children with acute megakaryoblastic leukemia (AMKL) remains poor, except for cases associated with Down syndrome (DS). This study compared immunophenotypic and drug sensitivity patterns of childhood AMKL cases with or without DS. All DS-AMKL cases showed high expression of CD36 and...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2006-10, Vol.47 (10), p.2076-2083
Main Authors: Sava an, Süreyya, Buck, Steven, Raimondi, Susana C., Becton, David L., Weinstein, Howard, Chang, Myron, Ravindranath, Yaddanapudi
Format: Article
Language:English
Subjects:
Adolescent
Adult
Biomarkers, Tumor
CD36
CD36 Antigens - biosynthesis
Cell Membrane - metabolism
Child
Child, Preschool
cytarabine
Cytarabine - pharmacology
daunorubicin
Daunorubicin - pharmacology
Down syndrome
Down Syndrome - complications
drug sensitivity
Gene Expression Regulation, Neoplastic
Humans
immunophenotype
Immunophenotyping
Infant
Infant, Newborn
Leukemia, Megakaryoblastic, Acute - complications
Leukemia, Megakaryoblastic, Acute - metabolism
Leukemia, Megakaryoblastic, Acute - pathology
Megakaryoblastic leukemia
Sensitivity and Specificity
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The outcome for children with acute megakaryoblastic leukemia (AMKL) remains poor, except for cases associated with Down syndrome (DS). This study compared immunophenotypic and drug sensitivity patterns of childhood AMKL cases with or without DS. All DS-AMKL cases showed high expression of CD36 and were very sensitive to cytarabine and daunorubicin in vitro. In children without DS, high expression of CD36 on AMKL blasts identified a sub-group with immunophenotypic and drug sensitivity patterns similar to that of DS AMKL. Among non-DS AMKL patients, CD36-high cases had a superior outcome compared with CD36-negative cases. CD36 expression in acute myeloid leukemia cases other than AMKL was not associated with increased in vitro drug sensitivity. CD36 expression in AMKL may be an indicator of megakaryoblast maturation and chemotherapy sensitivity.
ISSN:1042-8194
1029-2403
DOI:10.1080/10428190600773180